Ontario fund invests $1 million in Interface Biologics

The Ontario Government’s Investment Accelerator Fund-Life Sciences (IAF-LS), which helps accelerate the growth of life sciences companies in Ontario, has invested $1 million in closely held Interface Biologics. “We are very pleased that the IAF-LS has chosen Interface as one of the limited number of life sciences companies they are funding,” Interface CEO Tom Reeves [...]

Interface in licensing pact with Navilyst Medical

Closely held Interface Biologics has reached a definitive license and supply agreement with Navilyst Medical, giving it exclusive access to incorporate Interface’s Endexo technology in its vascular access products. Navilyst Medical is a leading manufacturer of image-guided medical technologies. Endexo is a bio-medical polymer additive that results in a passivating surface that reduces platelet adhesion, [...]

Fresenius executes pact for Interface Biologics license

Fresenius Medical Care (NYSE:FMS), the world’s largest integrated provider of dialysis products and services, has executed an option for an exclusive license to apply Interface Biologics’ Endexo technology to various components of its dialysis circuits for treating end-stage renal disease, including dialyzers and blood lines. The original accord in July, 2010 provided for an eight-to-12 [...]

Interface names Rosenthal as chairman

Closely held Interface Biologics of Toronto has appointed Arthur Rosenthal as chairman of the board.  Dr. Rosenthal, who joined the Interface board in March, 2010, is currently CEO of Cappella, a medical device company focused on coronary artery disease. He has also held senior scientific and R&D titles at Boston Scientific, J&J Medical and CR [...]

Interface Biologics raises $7 million

Closely held Interface Biologics of Toronto has completed a $7 million series B financing, led by Business Development Bank of Canada, in conjunction with Covington Capital and VG Partners. “Based on our current forecasts, this financing is sufficient for us to reach cash flow breakeven but we are still open to a $3 million-to-$5 million [...]

The deal’s the deal at Interface Biologics

Fresh from a potentially game-changing licensing deal with dialysis industry leader Fresenius Medical Care (FSE:FME; NYSE:FMS), closely held Interface Biologics still has more irons in the fire for its biomedical polymers to improve the safety and efficacy of blood-contacting medical devices. “What we’ve tried to do is select a few areas that represent big markets [...]

Interface Biologics licenses Endexo to Fresenius

Closely held Interface Biologics of Toronto has signed an evaluation and exclusive license option agreement with Germany’s Fresenius Medical Care (FSE:FME; NYSE:FMS), the world’s largest provider of dialysis products and services.  Under the accord, Fresenius will evaluate the use and efficacy of Interface’s Endexo technology to various components of its dialysis circuits for treating end-stage [...]